MitoSS-31 vs SS-31: What You're Actually Getting

“MitoSS-31” is a vendor product name, not a distinct molecule. The store’s own product page confirms the active compound is SS-31 — the same peptide known in the scientific literature as elamipretide, MTP-131, and Bendavia. So the honest question isn’t “does MitoSS-31 work?” but “what does the human evidence on SS-31 actually show, and is the vial you’d buy the same thing that was tested?”

What SS-31 actually is

SS-31 is a synthetic cell-penetrating tetrapeptide (D-Arg-Dmt-Lys-Phe-NH₂) that concentrates in the inner mitochondrial membrane. There it binds cardiolipin, a phospholipid essential to mitochondrial structure. By stabilizing cardiolipin, it helps preserve the folded cristae where energy production happens, supports assembly of respiratory complexes I, III, and IV, improves electron-transport efficiency, and reduces reactive oxygen species. On paper, that is an elegant fix for failing mitochondria.

The preclinical rationale is genuinely strong. The problem is that a strong mechanism has repeatedly failed to translate into wins in large human trials.

Despite a compelling mitochondrial mechanism, elamipretide missed its primary endpoints in its pivotal trials for mitochondrial myopathy, heart failure, and dry AMD.

What the human trials showed

The pattern across major programs is consistent: promising biology, disappointing pivotal results.

Trial	Condition	Result
MMPOWER-3	Primary mitochondrial myopathy	Missed both primary endpoints
PROGRESS-HF	Heart failure (HFrEF)	Missed primary endpoint (LVESV)
ReCLAIM	Dry AMD / geographic atrophy	Missed primary endpoints
TAZPOWER	Barth syndrome	Basis for a narrow accelerated approval

MMPOWER-3, published in Neurology in 2023, was the pivotal phase 3 test in genetically confirmed primary mitochondrial myopathy. It randomized roughly 218 participants and failed to show a significant benefit on either primary endpoint — the six-minute walk test and the PMMSA fatigue score. A later post hoc analysis suggested a possible signal in patients with nuclear-DNA mutations, but a post hoc subgroup is a hypothesis, not proof. In heart failure (PROGRESS-HF) and dry age-related macular degeneration (ReCLAIM), elamipretide likewise missed its primary endpoints, with only secondary or exploratory signals.

The one approval — and its limits

In September 2025 the FDA granted accelerated approval to elamipretide (brand name Forzinity, Stealth BioTherapeutics) for Barth syndrome, an ultra-rare genetic mitochondrial disease, based largely on the TAZPOWER program. It is described as the first cardiolipin-directed mitochondrial therapeutic. This matters, but note what it is not: an approval for aging, general fatigue, or “mitochondrial health.” Accelerated approval in one rare disease is a narrow, disease-specific decision — not evidence for the longevity uses SS-31 is marketed for online.

Why the product-vs-compound distinction matters

Even where the science is real, a research-grade “MitoSS-31” vial is not Forzinity. It is an unapproved, grey-market preparation not made or tested to pharmaceutical standards. You cannot assume identity, dose accuracy, or purity from the label. If you are evaluating such a product, the only meaningful check is a recent third-party certificate of analysis (COA) confirming the compound is in fact SS-31 at the stated purity — and even a clean COA doesn’t turn it into an approved drug.

The takeaway

SS-31 / elamipretide is a real, well-studied compound with a plausible mechanism and, as of 2025, a single narrow FDA approval for Barth syndrome. But its pivotal trials for the broader uses people actually buy it for have largely failed. “MitoSS-31” is a vendor label for research-grade SS-31 — not the clinical drug — so identity and purity are unverified until a COA proves otherwise. Judge it on the human data, which is mostly a record of disappointment outside one rare disease.

Sources

• Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential (PMC, 2025)
• Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial (Neurology, 2023)
• Elamipretide: the first cardiolipin-directed mitochondrial therapeutic for Barth syndrome approved under accelerated approval (PubMed, 2025)